Drug profile · INN
tocainide hydrochloride
TONOCARD
tocainide hydrochloride (TONOCARD) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
Drug details — tocainide hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
tocainide hydrochloride (TONOCARD) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is tocainide hydrochloride?
tocainide hydrochloride (TONOCARD) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tocainide hydrochloride?
TONOCARD is a marketed brand name for tocainide hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tocainide hydrochloride?
tocainide hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.